Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Article in Spanish | CUMED | ID: cum-79447

ABSTRACT

Fundamento:el dolor pélvico crónico es un problema ginecológico frecuente en las mujeres de edad fértil. Se define como el dolor no cíclico que persiste durante seis meses o más, localizado en la pelvis, en la porción infra umbilical de la pared abdominal anterior, en la región lumbosacra o en la región glútea lo que provoca discapacidad funcional. Las mujeres en edad fértil, son sin lugar a duda el grupo etario fundamental para la salud global y de las futuras generaciones. Muchas mujeres acuden a consulta de Ginecología por presentar dolor pelviano crónico y al realizarles la historia clínica, se observan problemas de fertilidad.Objetivo:caracterizar el comportamiento del dolor pélvico crónico de causa ginecológica en pacientes en edad fértil.Métodos:se realizó un estudio observacional, descriptivo, transversal. La población de estudio estuvo constituida por 123 mujeres con diagnóstico de dolor pélvico crónico de causa ginecológica y en edad fértil, que fueron atendidas en consulta de Ginecología en el Hospital Docente Clínico Quirúrgico Comandante Manuel Fajardo Rivero de Villa Clara durante el período comprendido entre el 1ro de septiembre de 2017 al 30 de septiembre de 2019.Resultados:las mujeres en el estudio eran adultas. La principal causa del dolor fue la endometriosis. La mayoría eran multíparas y presentaron infertilidad.Conclusiones:la mayoría de las pacientes con dolor pélvico crónico en edad fértil eran adultas. La principal causa del dolor pélvico crónico fue la endometriosis, seguido de las adherencias. La mayoría de las mujeres eran multíparas y presentaron infertilidad.[AU]


Subject(s)
Pelvic Pain , Women , Observational Studies as Topic , Endometriosis , Infertility, Female
2.
Br J Cancer ; 110(11): 2700-7, 2014 May 27.
Article in English | MEDLINE | ID: mdl-24786599

ABSTRACT

BACKGROUND: Sunitinib represents a widely used therapy for metastatic renal cell carcinoma patients. Even so, there is a group of patients who show toxicity without clinical benefit. In this work, we have analysed pivotal molecular targets involved in angiogenesis (vascular endothelial growth factor (VEGF)-A, VEGF receptor 2 (KDR), phosphorylated (p)KDR and microvascular density (MVD)) to test their potential value as predictive biomarkers of clinical benefit in sunitinib-treated renal cell carcinoma patients. METHODS: Vascular endothelial growth factor-A, KDR and pKDR-Y1775 expression as well as CD31, for MVD visualisation, were determined by immunohistochemistry in 48 renal cell carcinoma patients, including 23 metastatic cases treated with sunitinib. Threshold was defined for each biomarker, and univariate and multivariate analyses for progression-free survival (PFS) and overall survival (OS) were carried out. RESULTS: The HistoScore mean value obtained for VEGF-A was 121.6 (range, 10-300); for KDR 258.5 (range, 150-300); for pKDR-Y1775 10.8 (range, 0-65) and the mean value of CD31-positive structures for MVD visualisation was 49 (range, 10-126). Statistical differences for PFS (P=0.01) and OS (P=0.007) were observed for pKDR-Y1775 in sunitinib-treated patients. Importantly, pKDR-Y1775 expression remained significant after multivariate Cox analysis for PFS (P=0.01; HR: 5.35, 95% CI, 1.49-19.13) and for OS (P=0.02; HR: 5.13, 95% CI, 1.25-21.05). CONCLUSIONS: Our results suggest that the expression of phosphorylated (i.e., activated) KDR in tumour stroma might be used as predictive biomarker for the clinical outcome in renal cell carcinoma first-line sunitinib-treated patients.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Carcinoma, Renal Cell/blood supply , Indoles/therapeutic use , Kidney Neoplasms/blood supply , Neovascularization, Pathologic/metabolism , Pyrroles/therapeutic use , Adult , Aged , Aged, 80 and over , Angiogenesis Inhibitors/pharmacology , Biomarkers, Tumor/metabolism , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/secondary , Cohort Studies , Disease-Free Survival , Female , Humans , Indoles/pharmacology , Kaplan-Meier Estimate , Kidney Neoplasms/drug therapy , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Male , Microvessels/pathology , Middle Aged , Multivariate Analysis , Neovascularization, Pathologic/drug therapy , Phosphoproteins/metabolism , Proportional Hazards Models , Pyrroles/pharmacology , Sunitinib , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism
3.
Ann Oncol ; 23(5): 1156-1164, 2012 May.
Article in English | MEDLINE | ID: mdl-21908496

ABSTRACT

BACKGROUND: Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its associations with outcome are yet poorly characterized. PATIENTS AND METHODS: Quantitative expression of PARP-1 protein was assayed by a specific immunohistochemical signal intensity scanning assay in a range of normal to malignant breast lesions, including a series of patients (N = 330) with operable breast cancer to correlate with clinicopathological factors and long-term outcome. RESULTS: PARP-1 was overexpressed in about a third of ductal carcinoma in situ and infiltrating breast carcinomas. PARP-1 protein overexpression was associated to higher tumor grade (P = 0.01), estrogen-negative tumors (P < 0.001) and triple-negative phenotype (P < 0.001). The hazard ratio (HR) for death in patients with PARP-1 overexpressing tumors was 7.24 (95% CI; 3.56-14.75). In a multivariate analysis, PARP-1 overexpression was an independent prognostic factor for both disease-free (HR 10.05; 95% CI 5.42-10.66) and overall survival (HR 1.82; 95% CI 1.32-2.52). CONCLUSIONS: Nuclear PARP-1 is overexpressed during the malignant transformation of the breast, particularly in triple-negative tumors, and independently predicts poor prognosis in operable invasive breast cancer.


Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/mortality , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/mortality , Cell Nucleus/metabolism , Poly(ADP-ribose) Polymerases/metabolism , Adult , Aged , Aged, 80 and over , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Breast Neoplasms/diagnosis , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Ductal, Breast/pathology , Cell Nucleus/pathology , Cells, Cultured , Disease Progression , Embryo, Mammalian , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mice , Mice, Knockout , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerase Inhibitors , Poly(ADP-ribose) Polymerases/genetics , Prognosis , RNA, Small Interfering/pharmacology , Survival Analysis , Up-Regulation/drug effects , Up-Regulation/genetics
4.
Vet Immunol Immunopathol ; 83(3-4): 191-202, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11730929

ABSTRACT

Cytokines play an important role in the regulation of the immune system, but low circulating levels in plasma make routine measurement a difficult task. A new methodology based on single tube RT-PCR has been developed to determine the expression of multiple canine cytokines (TNF-alpha, IL-2, IFN-gamma, IL-18, IL-4, IL-6 and IL-10) using primers and protocols designed allow specific amplification of the mRNAs. The technique is performed in one tube in two consecutive steps, a specific transcription of the mRNA of a given cytokine and amplification of the corresponding gene by PCR. The technique was used to analyse the mRNA cytokine profile of peripheral blood mononuclear cells (PBMCs) from healthy dogs using two approaches: (i) analysis of PBMC isolated ex vivo; (ii) analysis of PBMC after in vitro cultures with or without the mitogen ConA. The samples were separated in agarose gels and the intensity of ethidium bromide signals quantified using standard video imaging equipment. Results were interpreted as the ratio of cytokine to GAPDH expression. The results obtained show that the method is easy to use and reproducible. Therefore, this method of monitoring the mRNA cytokine expression might be an useful tool for understanding the immune response in dogs.


Subject(s)
Cytokines/blood , Dogs/immunology , Reverse Transcriptase Polymerase Chain Reaction/veterinary , Animals , Cytokines/biosynthesis , Cytokines/genetics , DNA/blood , DNA/genetics , Dogs/blood , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , RNA, Messenger/blood , RNA, Messenger/genetics , Sequence Analysis, DNA
5.
Trans R Soc Trop Med Hyg ; 94(3): 328-32, 2000.
Article in English | MEDLINE | ID: mdl-10975014

ABSTRACT

Specific serum antibodies, peripheral blood T-cell subsets, cellular response in vitro to soluble Leishmania antigens, phenotype of stimulated cells, and serum levels of tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta 1 were studied in Spain in 17 patients co-infected with HIV and Leishmania infantum who had been previously treated with pentavalent antimony. Both humoral and cellular responses to Leishmania sp. appeared diminished, 8 out of 17 patients were positive by indirect immunofluorescence, and immunoblotting detected heterogeneous antibody-binding pattern in 11 out of 13 subjects. A blastogenesis test was positive in 4 cases; 2 of them presented proliferation of CD4+ cells while CD8+ cells proliferated in the other 2 patients. Serum levels of TNF-alpha were similar to those observed in patients infected with HIV only, while serum levels of TGF-beta 1 were significantly lower in the co-infected patients. The inability of antibody response to control the parasite and the absence of specific T-cell immunity to Leishmania sp. would explain the high frequency of relapses reported in these patients. The decreased levels of TGF-beta 1 could have an important role in the interaction between the 2 pathogens.


Subject(s)
AIDS-Related Opportunistic Infections/immunology , Antibodies, Protozoan/analysis , Leishmania infantum/immunology , Leishmaniasis, Visceral/immunology , Animals , CD4-CD8 Ratio , Cytokines/immunology , Fluorescent Antibody Technique, Indirect , Humans , Immunity, Cellular , Leishmaniasis, Visceral/drug therapy , Leukocytes, Mononuclear/immunology , T-Lymphocyte Subsets/immunology
6.
Vet Immunol Immunopathol ; 71(3-4): 181-95, 1999 Nov 30.
Article in English | MEDLINE | ID: mdl-10587300

ABSTRACT

Peripheral blood mononuclear cell subsets, in vitro lymphoproliferative response to leishmanial antigen, and Leishmania-specific serum antibody levels were examined in 11 dogs, naturally infected with L. infantum, and 9 healthy control dogs. A decrease in the percentage of CD4+ T-cells and an increase in the proportion of gammadelta T-cells and sIgG+ B-cells were observed during canine visceral leishmaniasis (CVL). These changes may be responsible for the marked humoral response and the absence of in vitro lymphoproliferation to mitogen and specific parasite antigens. This possibility was supported by the analysis of these subsets after treatment with amphotericin B. One month after therapy, a significant increase in the percentage of CD4+ T-cells and a decrease of gammadelta T-cells and sIgG+ B-cells were observed. At the same time, the lymphocyte blastogenesis assay with leishmanial antigen was positive and the levels of specific antibodies to Leishmania were significantly lower than before the treatment. Five months after therapy, lymphocyte proliferative response to LSA disappeared, antibody and lymphocyte subsets levels returned to those observed during CVL. Therapeutic failure in CVL is associated with the inability of antileishmanial drugs to completely revert the profound immunodepression induced by the infection and prevent relapse.


Subject(s)
Dog Diseases/immunology , Leishmaniasis, Visceral/veterinary , Leukocytes, Mononuclear/immunology , Amphotericin B/therapeutic use , Animals , Dog Diseases/drug therapy , Dogs , Female , Immune Tolerance , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/immunology , Male , Receptors, Antigen, T-Cell, gamma-delta/analysis
7.
Acta Neurol Scand ; 96(6): 375-9, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9449475

ABSTRACT

The objective of this study was to ascertain the prevalence and incidence of Multiple Sclerosis (MS) in a population of 33,775 in two primary health care centres in the sanitary district of Gijon, Asturias, northern Spain. Many information sources were used but the unique advantage of Gijon was that the city has a centralized computerized register of all diagnoses made for all consultations in the clinics and hospitals in the area. The HLA distribution in the population was already known and the Poser classification of MS was used. The crude MS prevalence was 65/100,000, a similar prevalence to that found in southern and eastern Spain, Sicily and Greek-speaking Cyprus. The mean incidence was 3.7/100,000 per year. The study demonstrated the advantage of a centralized and computerized medical recording system and demonstrates that northern Spain is a moderately high or medium MS risk zone.


Subject(s)
Multiple Sclerosis/epidemiology , Adolescent , Adult , Age Distribution , Aged , Confidence Intervals , Cross-Sectional Studies , Female , Humans , Incidence , Male , Middle Aged , Prevalence , Prospective Studies , Registries , Retrospective Studies , Sex Distribution , Spain/epidemiology
9.
FEMS Microbiol Lett ; 135(1): 45-50, 1996 Jan 01.
Article in English | MEDLINE | ID: mdl-8598276

ABSTRACT

We have studied the influence of sigma s on the stability and number of copies of the promiscuous plasmid pLS1 in Escherichia coli. Our results indicate that pLS1 is less stable and has a lower number of copies in a rpoS mutant than in a wild-type strain during stationary phase. This behaviour does not seem to be due to differences in the expression of pLS1 replication regulators, but to be related to plasmid topology.


Subject(s)
Bacterial Proteins/physiology , Escherichia coli/growth & development , Plasmids/physiology , Sigma Factor/physiology , DNA, Bacterial/metabolism , Escherichia coli/genetics , Plasmids/ultrastructure , Promoter Regions, Genetic , S Phase
SELECTION OF CITATIONS
SEARCH DETAIL
...